Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study

BACKGROUND: An open‐label single‐arm phase 2 study was conducted to evaluate the role of levetiracetam as a sensitizer of concurrent chemoradiotherapy (CCRT) for patients with newly diagnosed glioblastoma. This study aimed to determine the survival benefit of levetiracetam in conjunction with the st...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Kihwan, Kim, Junhyung, Kang, Seok‐Gu, Jung, Tae‐Young, Kim, Jeong Hoon, Kim, Se‐Hyuk, Kang, Shin‐Hyuk, Hong, Yong‐Kil, Kim, Tae Min, Kim, Yu Jung, Choi, Byung Se, Chang, Jong Hee, Kim, Chae‐Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729048/
https://www.ncbi.nlm.nih.gov/pubmed/34845868
http://dx.doi.org/10.1002/cam4.4454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729048/
https://www.ncbi.nlm.nih.gov/pubmed/34845868
http://dx.doi.org/10.1002/cam4.4454

Ejemplares similares